A new vaccine to improve tuberculosis prevention
A novel c-di-AMP-based recombinant BCG vaccine
['FUNDING_R21'] · ALBANY MEDICAL COLLEGE · NIH-10783087
This study is looking to create a better vaccine for tuberculosis (TB) by using a special ingredient that helps boost the immune system, aiming to offer stronger protection for people who are at risk of getting TB.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ALBANY MEDICAL COLLEGE (nih funded) |
| Locations | 1 site (ALBANY, UNITED STATES) |
| Trial ID | NIH-10783087 on ClinicalTrials.gov |
What this research studies
This research aims to develop a more effective vaccine for tuberculosis (TB) by utilizing a novel recombinant Bacillus Calmette-Guérin (BCG) vaccine that incorporates cyclic di-AMP (c-di-AMP), a bacterial signaling molecule. The study investigates how enhancing the immune response through c-di-AMP can improve the vaccine's effectiveness against TB. By understanding the biological differences between the TB-causing bacteria and the current BCG vaccine, the researchers hope to create a vaccine that provides better protection for individuals at risk of TB.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of tuberculosis infection, including those in endemic regions or with compromised immune systems.
Not a fit: Patients who are not at risk for tuberculosis or those who have already been vaccinated with BCG may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective TB vaccine, significantly reducing the incidence of the disease.
How similar studies have performed: Other research has shown promise in using novel adjuvants like c-di-AMP to enhance vaccine efficacy, indicating a potential for success in this approach.
Where this research is happening
ALBANY, UNITED STATES
- ALBANY MEDICAL COLLEGE — ALBANY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BAI, GUANGCHUN — ALBANY MEDICAL COLLEGE
- Study coordinator: BAI, GUANGCHUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.